Director Holdings

RNS Number : 7208R

Proteome Sciences PLC

08 November 2011

 



Proteome Sciences plc

Directors dealings

8^th November 2011 Proteome Sciences plc ("Proteome") is pleased to announce that on 7 November it granted options under its 2011 Long Term Incentive Plan to certain directors. The details of the option grants are set out below:

Name	Title	Exercise price	Number of options	Total number of options held post grant	% of issued share capital
Christopher Pearce	Chief Executive Officer	1p	1,174,269	1,451,343	0.75
Ian Pike	Chief Operating Officer	1p	654,971	902,141	0.47
James Malthouse	Finance Director	1p	767,251	1,025,559	0.53

For further information please contact:

Proteome Sciences plc
www.proteomics.com	Tel: [phone]
Christopher Pearce, Chief Executive Officer	[e-mail]
James Malthouse, Finance Director	[e-mail]
Dr. Ian Pike, Chief Operating Officer	[e-mail]
Nominated Adviser
Singer Capital Markets Limited	Tel: [phone]
Shaun Dobson/Claes Spång
Public Relations
FTI Consulting	IKON Associates
Ben Atwell/Mo Noonan	Adrian Shaw
Tel:       [phone]	Tel:       [phone]
Email:   [e-mail]	Mobile:  [phone]
	Email:   [e-mail]

Notes to Editors:

About Proteome Sciences

Proteome Sciences is a global leader in applied proteomics and peptidomics offering high sensitivity, proprietary technologies for protein and peptide biomarker discovery, validation and assay development.

Its PS Biomarker Services™ uses isobaric and isotopic Tandem Mass Tag^® (TMT^®) workflows developed on the latest Orbitrap Velos and TSQ Vantage mass spectrometers to deliver rapid, robust and reproducible biomarker assay development for customers in the pharmaceutical, diagnostic and biotechnology sectors. Services are provided from its ISO 9001: 2008 accredited facilities in Frankfurt, Germany. By combining Selected Reaction Monitoring (SRM) and TMT workflows highly multiplexed assays can be developed rapidly and are suitable for screening hundreds of candidate biomarkers in larger validation studies and can be transferred for immunoassay development. The Company's own research has discovered a large number of novel protein biomarkers in key human diseases and is focused mainly in neurological/neurodegenerative conditions and in cancer. It has discovered and patented blood biomarkers, including Alzheimer's disease, stroke, brain damage and lung cancer for diagnostic and treatment applications that are available for license or are already outlicensed. Proteome Sciences, based in Cobham, UK, with facilities in London and Frankfurt, delivers outsourced proteomics services and proprietary biomarkers/biomarker assays to pharmaceutical, biotechnology and diagnostics companies.

Visit:  http://www.proteomics.com.

 

END

 

 

RDSLLFVELVLTIIL